These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2516634)

  • 1. Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates.
    Casey DE
    Psychopharmacol Bull; 1989; 25(3):457-9. PubMed ID: 2516634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates.
    Casey DE
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S55-9. PubMed ID: 7831441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrapyramidal syndromes in nonhuman primates: typical and atypical neuroleptics.
    Casey DE
    Psychopharmacol Bull; 1991; 27(1):47-50. PubMed ID: 1677773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors.
    Coffin VL; Latranyi MB; Chipkin RE
    J Pharmacol Exp Ther; 1989 Jun; 249(3):769-74. PubMed ID: 2567351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates.
    Casey DE; Bruhwyler J; Delarge J; Géczy J; Liégeois JF
    Psychopharmacology (Berl); 2001 Sep; 157(3):228-35. PubMed ID: 11605077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of acute neuroleptic-induced movement disorders.
    Tonda ME; Guthrie SK
    Pharmacotherapy; 1994; 14(5):543-60. PubMed ID: 7997388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor and mental aspects of extrapyramidal syndromes.
    Casey DE
    Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():105-14. PubMed ID: 8866772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial.
    Wynchank D; Berk M
    Hum Psychopharmacol; 2003 Jun; 18(4):271-5. PubMed ID: 12766931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergism of theophylline and anticholinergics to inhibit haloperidol-induced catalepsy: a potential treatment for extrapyramidal syndromes.
    González-Lugo OE; Ceballos-Huerta F; Jiménez-Capdeville ME; Arankowsky-Sandoval G; Góngora-Alfaro JL
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1465-71. PubMed ID: 20713114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
    Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
    Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
    Nasrallah HA; Brecher M; Paulsson B
    Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys.
    Casey DE
    Psychopharmacology (Berl); 1992; 107(1):18-22. PubMed ID: 1534177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys.
    Andersen MB; Fuxe K; Werge T; Gerlach J
    Behav Pharmacol; 2002 Dec; 13(8):639-44. PubMed ID: 12478214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin(1A) receptor agonism in the expression of behavioral dopaminergic supersensitivity in subchronic haloperidol treated rats.
    Batool F; Haleem DJ
    Pak J Pharm Sci; 2008 Oct; 21(4):411-20. PubMed ID: 18930864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of D1 (NNC 22-0215) and D2 (haloperidol) antagonists in a chronic double-blind placebo controlled trial in cebus monkeys.
    Casey DE
    Psychopharmacology (Berl); 1995 Oct; 121(3):289-93. PubMed ID: 8584608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of extrapyramidal symptoms during acute neuroleptic treatment.
    Mazure CM; Cellar JS; Bowers MB; Nelson JC; Takeshita J; Zigun B
    J Clin Psychiatry; 1995 Mar; 56(3):94-100. PubMed ID: 7883736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tryptophan and valine administration on behavioral pharmacology of haloperidol.
    Ali O; Haleem DJ; Saify ZS; Kamil N; Obaid R; Ahmed SW
    Pak J Pharm Sci; 2005 Apr; 18(2):23-8. PubMed ID: 16431394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonergic involvement in haloperidol-induced catalepsy.
    Neal-Beliveau BS; Joyce JN; Lucki I
    J Pharmacol Exp Ther; 1993 Apr; 265(1):207-17. PubMed ID: 8386235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in rats.
    Haleem DJ; Khan NH
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):645-51. PubMed ID: 12787852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the effects of haloperidol and clozapine on brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats.
    Haleem DJ; Batool F; Khan NH; Kamil N; Ali O; Saify ZS; Haleem MA
    Med Sci Monit; 2002 Sep; 8(9):BR354-61. PubMed ID: 12218936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.